Common and Differentiated Representations Between Social Exclusion and Social Separation

University of Electronic Science and Technology of China

Status: Enrolling

Conditions: Healthy

Treatments: Drug: Intranasal Oxytocin; Drug: Intranasal placebo; Drug: Intranasal Arginine Vasopressin

Study type: Interventional

Funder types: Other

Identifiers

NCT05920707

UESTC-neuSCAN-93

Details and patient eligibility

About

Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.

Full description

A large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. In addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. Therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. In this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fMRI) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of OXT/AVP on them (PLC/24IU OXT/20IU AVP).

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy subjects;
2. Without any past or present psychiatric or neurological disorders;
3. Without any current psychotherapeutic medication.

Exclusion criteria

1. With any past or present psychiatric or neurological disorders;
2. With any current psychotherapeutic medication.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

120 participants in 4 patient groups, including a placebo group

Intranasal Oxytocin

Active Comparator group

Description:

Administer oxytocin (24 IU) intranasally.

Treatment:

Drug: Intranasal Oxytocin

Intranasal Arginine Vasopressin

Active Comparator group

Description:

Administer Arginine Vasopressin (20 IU) intranasally.

Treatment:

Drug: Intranasal Arginine Vasopressin

Intranasal placebo

Placebo Comparator group

Description:

Administer placebo intranasally.

Treatment:

Drug: Intranasal placebo

Intranasal nothing (control)

No Intervention group

Description:

Control condition